High amphiregulin expression has been suggested as a positive predictor of sensitivity to anti-EGFR drugs in NSCLC patients, whose tumour had the P-EGFR gene (Yonesaka et al, 2008). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.